Minimal Residual Disease (MRD) Testing Market Size Worth USD 7.20 billion by 2034 | CAGR of 13.1%

Polaris Market Research has released a new industry study estimating the global Minimal Residual Disease (MRD) Testing market at USD 2.38 billion in 2025, with the market on track to touch USD 7.20 billion by 2034 at a CAGR of 13.1% across the forecast window.

Industry Overview:

Demand for minimal residual disease (MRD) testing has been on an upward trajectory as oncologists increasingly rely on highly sensitive molecular tools to assess treatment response and relapse risk in blood cancers. Vendors are responding with expanded assay portfolios, deeper hospital and laboratory partnerships, and continued investment in next-generation sequencing (NGS) platforms to improve turnaround time and detection sensitivity. Policy support in the form of an improving regulatory and reimbursement environment for NGS-based diagnostics, paired with growing private capital inflows into precision oncology, is reinforcing this momentum, and providers are increasingly weighing testing accuracy and standardization alongside cost.

Get a Free Sample of the Minimal Residual Disease Testing Market Report → Request Sample Report:
https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market

Growth Drivers & Emerging Trends:

A combination of structural and clinical factors is underpinning expansion. Rising global cancer incidence and increased R&D spending are lifting baseline demand for MRD testing, while established markets see steady adoption of MRD as a standard-of-care tool in leukemia, lymphoma, and multiple myeloma management. Precision medicine is a recurring theme: patient-specific molecular monitoring, quantification of residual cancer cells, and risk-adapted treatment decisions are becoming standard rather than optional. The expansion of liquid biopsy and ctDNA-based approaches into solid tumors is also nudging procurement toward more sensitive, less invasive monitoring solutions.

Restraints and Headwinds:

Growth is not without friction. The high cost of MRD assays, which can run into the thousands of dollars per test, remains a barrier for smaller laboratories and cost-sensitive health systems, and the need for serial testing adds further expense. A lack of standardized operating procedures across institutions complicates uniform interpretation of results, and limited or inconsistent reimbursement policies for MRD testing - which vary by cancer type and geography - continue to slow broader clinical adoption.

Opportunity Landscape:

Underpenetrated opportunities in liquid biopsy and the expansion of MRD testing into solid tumor types such as lung, breast, and colorectal cancer represent meaningful whitespace as ctDNA-based assays mature. Growing use of MRD as a clinical trial endpoint in drug development, along with rising demand in stem cell transplant and CAR-T monitoring, are emerging as additional avenues for market expansion beyond traditional hematologic malignancies. Vendors that pair strong NGS and bioinformatics capabilities with credible clinical validation data are best positioned to capture share as providers consolidate around fewer, more strategic diagnostic partners.

Segmental Analysis:

➢ By Detection Type Outlook (USD Billion, 2021-2034)
• Lymphoma
• Leukemia
• Solid Tumors
• Multiple Myeloma
• Others

➢ By Test Technique Outlook (USD Billion, 2021-2034)
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

➢ By End User Outlook (USD Billion, 2021-2034)
• Hospitals and Specialty Clinics
• Laboratory Centres

Regional Outlook:

North America currently accounts for the largest revenue share, aided by strong patient and physician awareness, widespread adoption of advanced screening technologies, and established reimbursement pathways. Asia Pacific is forecast to post the fastest growth over the study period as rising disease incidence, aging populations, and improving diagnostic infrastructure in economies such as China and India scale up demand for MRD testing. Europe's growth is more measured but steady, anchored by advanced healthcare infrastructure and rising investment in precision medicine, while Latin America and the Middle East & Africa are starting from a smaller base but drawing increasing vendor attention.

👉 Explore the Full Minimal Residual Disease Testing Market Report → Buy Now / Speak to an Analyst:
https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/pricing

Vendor Landscape:

Competitive intensity is moderate to high, with a mix of established diagnostics multinationals, genomics firms, and specialized laboratories vying for share. Differentiation increasingly hinges on assay sensitivity, turnaround time, and the ability to expand testing into solid tumors, rather than technology alone. Companies are pursuing a mix of platform expansion, acquisitions, and strategic partnerships with hospitals and pharmaceutical companies to defend and grow their positions.

Key companies profiled in the study include:
• Adaptive Biotechnologies
• ArcherDX
• ARUP Laboratories
• Asuragen
• Bio-Rad Laboratories
• Cergentis
• F. Hoffmann-La Roche Ltd.
• Genetron Health
• GRAIL, LLC
• Guardant Health
• ICON plc (MolecularMD
• Inivata
• Invivoscribe

Latest Industry Updates:

• May 2026: Illumina launched its first distributed whole-genome sequencing solution for MRD research, enabling faster and highly sensitive cancer detection across solid tumors and blood cancers.

• September 2026: MedGenome launched OncoTrack MRD, a personalized, ultrasensitive blood-based test that uses patient-specific tumor signals to identify potential cancer recurrence earlier.

More Trending Latest Reports By Polaris Market Research:

➺ Sterile Injectable Contract Manufacturing Market
https://www.polarismarketresearch.com/industry-analysis/sterile-injectable-contract-manufacturing-market

➺ High Throughput Screening Market
https://www.polarismarketresearch.com/industry-analysis/high-throughput-screening-market

➺ Arbovirus Testing Market
https://www.polarismarketresearch.com/industry-analysis/arbovirus-testing-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc.

Polaris Market Research is a global market intelligence and consulting company dedicated to delivering in-depth business insights and actionable research. We specialize in providing syndicated reports, customized consulting solutions, and strategic advisory services across diverse industries - including healthcare, chemicals, energy, automotive, technology, and consumer goods. Our research methodology combines quantitative data with qualitative expertise, ensuring our clients receive accurate market sizing, growth forecasts, competitive analysis, and emerging trend insights. With a commitment to transparency, data accuracy, and client satisfaction, Polaris Market Research has become a trusted partner to leading corporations, consulting firms, and government organizations worldwide. We help businesses make informed strategic decisions, mitigate risk, and identify new growth opportunities in rapidly evolving markets.

This release was published on openPR.